A Novel Polyamine-Targeted Therapy for BRAF Mutant Melanoma Tumors

A Novel Polyamine-Targeted Therapy for BRAF Mutant Melanoma Tumors

Mutant serine/threonine protein kinase B-Raf (BRAF) protein is expressed in over half of all melanoma tumors. Although BRAF inhibitors (BRAFi) elicit rapid anti-tumor responses in the majority of patients with mutant BRAF melanoma, the tumors inevitably relapse after a short time. We hypothesized th...

Full description

Bibliographic Details
Main Authors: Molly C. Peters, Allyson Minton, Otto Phanstiel IV, Susan K. Gilmour
Format: Article
Language:English
Published: MDPI AG 2018-01-01
Series:Medical Sciences
Subjects:
polyamines
α-difluoromethylornithine
polyamine transport system
melanoma
mutant BRAF
Online Access:http://www.mdpi.com/2076-3271/6/1/3

Similar Items

Similar Items